Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Psoriasis | 325 | 2021 | 360 | 80.700 |
Why?
|
Dermatologic Agents | 189 | 2021 | 229 | 50.200 |
Why?
|
Dermatology | 116 | 2021 | 164 | 28.750 |
Why?
|
Dermatitis, Atopic | 72 | 2020 | 104 | 23.610 |
Why?
|
Acne Vulgaris | 75 | 2021 | 96 | 23.350 |
Why?
|
Skin Diseases | 85 | 2021 | 144 | 20.960 |
Why?
|
Medication Adherence | 73 | 2020 | 161 | 20.690 |
Why?
|
Biological Products | 47 | 2021 | 78 | 16.780 |
Why?
|
Rosacea | 38 | 2019 | 46 | 16.280 |
Why?
|
Humans | 819 | 2021 | 32297 | 15.720 |
Why?
|
Antibodies, Monoclonal | 44 | 2020 | 250 | 11.250 |
Why?
|
Glucocorticoids | 39 | 2019 | 161 | 10.880 |
Why?
|
Anti-Inflammatory Agents | 39 | 2020 | 102 | 10.640 |
Why?
|
Severity of Illness Index | 130 | 2020 | 926 | 10.380 |
Why?
|
Patient Compliance | 47 | 2020 | 227 | 10.260 |
Why?
|
Skin Neoplasms | 45 | 2020 | 214 | 9.310 |
Why?
|
Ultraviolet Therapy | 34 | 2019 | 40 | 9.140 |
Why?
|
Phototherapy | 35 | 2020 | 51 | 8.610 |
Why?
|
United States | 197 | 2021 | 3983 | 8.470 |
Why?
|
Administration, Topical | 84 | 2020 | 140 | 8.060 |
Why?
|
Administration, Cutaneous | 75 | 2020 | 117 | 8.060 |
Why?
|
Physician-Patient Relations | 38 | 2019 | 188 | 8.000 |
Why?
|
Quality of Life | 80 | 2021 | 915 | 8.000 |
Why?
|
Treatment Outcome | 135 | 2021 | 3358 | 7.880 |
Why?
|
Anti-Bacterial Agents | 35 | 2020 | 309 | 7.650 |
Why?
|
Adrenal Cortex Hormones | 30 | 2020 | 163 | 7.610 |
Why?
|
Skin | 29 | 2020 | 217 | 7.530 |
Why?
|
Adult | 249 | 2021 | 9467 | 7.510 |
Why?
|
Health Care Costs | 34 | 2020 | 118 | 7.430 |
Why?
|
Female | 320 | 2021 | 20126 | 7.280 |
Why?
|
Male | 306 | 2021 | 19488 | 7.140 |
Why?
|
Patient Satisfaction | 37 | 2020 | 245 | 7.130 |
Why?
|
Health Care Surveys | 60 | 2020 | 187 | 6.740 |
Why?
|
Middle Aged | 224 | 2021 | 11949 | 6.730 |
Why?
|
Patient Education as Topic | 34 | 2019 | 276 | 6.460 |
Why?
|
Office Visits | 39 | 2017 | 73 | 6.240 |
Why?
|
Retinoids | 27 | 2019 | 41 | 6.050 |
Why?
|
Adolescent | 136 | 2020 | 3571 | 5.910 |
Why?
|
Ambulatory Care | 33 | 2018 | 108 | 5.820 |
Why?
|
Desoximetasone | 10 | 2020 | 10 | 5.760 |
Why?
|
Clobetasol | 21 | 2020 | 26 | 5.720 |
Why?
|
Immunosuppressive Agents | 29 | 2020 | 238 | 5.110 |
Why?
|
Young Adult | 88 | 2020 | 2626 | 5.110 |
Why?
|
Methotrexate | 28 | 2020 | 64 | 5.060 |
Why?
|
Calcitriol | 18 | 2020 | 25 | 4.980 |
Why?
|
Immunologic Factors | 22 | 2021 | 49 | 4.860 |
Why?
|
Practice Guidelines as Topic | 32 | 2020 | 410 | 4.800 |
Why?
|
Clinical Trials as Topic | 39 | 2019 | 316 | 4.600 |
Why?
|
Benzoyl Peroxide | 16 | 2021 | 19 | 4.570 |
Why?
|
Keratolytic Agents | 24 | 2018 | 29 | 4.460 |
Why?
|
Drug Costs | 22 | 2020 | 47 | 4.340 |
Why?
|
Keratosis, Actinic | 11 | 2021 | 20 | 4.220 |
Why?
|
Acitretin | 17 | 2018 | 18 | 4.140 |
Why?
|
Arthritis, Psoriatic | 20 | 2019 | 25 | 4.140 |
Why?
|
Dermatitis, Allergic Contact | 10 | 2019 | 15 | 4.100 |
Why?
|
Child | 85 | 2020 | 2472 | 3.920 |
Why?
|
Aged | 134 | 2021 | 10398 | 3.910 |
Why?
|
Drug Prescriptions | 17 | 2017 | 54 | 3.830 |
Why?
|
Health Expenditures | 11 | 2020 | 66 | 3.700 |
Why?
|
Internship and Residency | 12 | 2019 | 306 | 3.460 |
Why?
|
Betamethasone | 12 | 2020 | 53 | 3.440 |
Why?
|
Internet | 17 | 2019 | 203 | 3.310 |
Why?
|
Retrospective Studies | 67 | 2020 | 3514 | 3.280 |
Why?
|
Erythema | 11 | 2019 | 27 | 3.260 |
Why?
|
Cost-Benefit Analysis | 38 | 2018 | 187 | 3.160 |
Why?
|
Nicotinic Acids | 7 | 2020 | 8 | 3.110 |
Why?
|
Depression | 17 | 2021 | 436 | 3.010 |
Why?
|
Drug Monitoring | 14 | 2019 | 26 | 2.890 |
Why?
|
Ultraviolet Rays | 16 | 2020 | 50 | 2.850 |
Why?
|
Boron Compounds | 6 | 2020 | 11 | 2.810 |
Why?
|
Randomized Controlled Trials as Topic | 28 | 2021 | 511 | 2.800 |
Why?
|
Pruritus | 14 | 2020 | 64 | 2.800 |
Why?
|
Drug Therapy, Combination | 33 | 2019 | 301 | 2.800 |
Why?
|
Biological Factors | 7 | 2020 | 11 | 2.780 |
Why?
|
Drug Utilization | 15 | 2018 | 49 | 2.680 |
Why?
|
Facial Dermatoses | 9 | 2019 | 18 | 2.680 |
Why?
|
Thalidomide | 7 | 2019 | 31 | 2.680 |
Why?
|
Immunoglobulin G | 20 | 2013 | 121 | 2.670 |
Why?
|
Cost of Illness | 17 | 2020 | 70 | 2.640 |
Why?
|
Insurance, Health | 12 | 2020 | 97 | 2.590 |
Why?
|
Patient Acceptance of Health Care | 11 | 2020 | 171 | 2.590 |
Why?
|
Communication | 11 | 2019 | 140 | 2.550 |
Why?
|
Patient Preference | 13 | 2019 | 48 | 2.540 |
Why?
|
Naphthalenes | 8 | 2021 | 40 | 2.510 |
Why?
|
Home Care Services | 7 | 2020 | 53 | 2.500 |
Why?
|
Tumor Necrosis Factor-alpha | 14 | 2019 | 213 | 2.480 |
Why?
|
Administration, Oral | 25 | 2019 | 185 | 2.460 |
Why?
|
Self Care | 10 | 2019 | 145 | 2.440 |
Why?
|
Prevalence | 38 | 2021 | 986 | 2.370 |
Why?
|
Child, Preschool | 44 | 2020 | 1281 | 2.370 |
Why?
|
Databases, Factual | 25 | 2020 | 355 | 2.360 |
Why?
|
Comorbidity | 23 | 2020 | 572 | 2.360 |
Why?
|
Prescription Drugs | 6 | 2020 | 20 | 2.320 |
Why?
|
Biological Therapy | 9 | 2020 | 22 | 2.280 |
Why?
|
Double-Blind Method | 27 | 2021 | 550 | 2.280 |
Why?
|
Scalp Dermatoses | 6 | 2016 | 18 | 2.240 |
Why?
|
Sunbathing | 5 | 2018 | 6 | 2.240 |
Why?
|
Receptors, Tumor Necrosis Factor | 20 | 2013 | 49 | 2.200 |
Why?
|
Quality of Health Care | 9 | 2018 | 151 | 2.150 |
Why?
|
Drug Administration Schedule | 27 | 2019 | 279 | 2.110 |
Why?
|
Ambulatory Surgical Procedures | 12 | 2013 | 27 | 2.080 |
Why?
|
Antirheumatic Agents | 12 | 2020 | 30 | 2.080 |
Why?
|
Oxymetazoline | 4 | 2019 | 4 | 2.040 |
Why?
|
PUVA Therapy | 19 | 2017 | 22 | 2.030 |
Why?
|
Publishing | 4 | 2020 | 63 | 2.000 |
Why?
|
Drug Design | 8 | 2020 | 47 | 1.960 |
Why?
|
Anti-Infective Agents | 7 | 2017 | 43 | 1.950 |
Why?
|
Interleukin-17 | 5 | 2019 | 27 | 1.910 |
Why?
|
Tretinoin | 8 | 2014 | 34 | 1.890 |
Why?
|
Biopsy | 8 | 2019 | 273 | 1.880 |
Why?
|
Eczema | 7 | 2020 | 13 | 1.860 |
Why?
|
Drug Combinations | 17 | 2021 | 93 | 1.850 |
Why?
|
Hand Dermatoses | 6 | 2010 | 10 | 1.810 |
Why?
|
Age Factors | 31 | 2020 | 1204 | 1.800 |
Why?
|
Pyrroles | 8 | 2018 | 57 | 1.790 |
Why?
|
Agricultural Workers' Diseases | 15 | 2013 | 85 | 1.770 |
Why?
|
Risk Assessment | 27 | 2019 | 1447 | 1.770 |
Why?
|
Pyrimidines | 8 | 2018 | 65 | 1.770 |
Why?
|
Metronidazole | 8 | 2017 | 15 | 1.770 |
Why?
|
Inflammatory Bowel Diseases | 3 | 2018 | 29 | 1.720 |
Why?
|
Sunscreening Agents | 6 | 2020 | 13 | 1.710 |
Why?
|
Medicare | 19 | 2020 | 206 | 1.690 |
Why?
|
Lymphoma | 5 | 2018 | 35 | 1.650 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2019 | 77 | 1.640 |
Why?
|
Isotretinoin | 7 | 2014 | 12 | 1.610 |
Why?
|
Periodicals as Topic | 5 | 2020 | 101 | 1.600 |
Why?
|
Time Factors | 27 | 2020 | 2181 | 1.590 |
Why?
|
Aged, 80 and over | 37 | 2020 | 4050 | 1.580 |
Why?
|
Skin Care | 5 | 2019 | 13 | 1.570 |
Why?
|
Evidence-Based Medicine | 18 | 2021 | 217 | 1.550 |
Why?
|
Fluorouracil | 4 | 2020 | 82 | 1.550 |
Why?
|
Pain | 10 | 2020 | 305 | 1.550 |
Why?
|
Bibliometrics | 3 | 2020 | 12 | 1.520 |
Why?
|
Pediatrics | 9 | 2020 | 158 | 1.510 |
Why?
|
Drug Industry | 5 | 2019 | 17 | 1.510 |
Why?
|
Cosmetic Techniques | 4 | 2018 | 11 | 1.500 |
Why?
|
Pyoderma Gangrenosum | 4 | 2017 | 12 | 1.500 |
Why?
|
Physician's Role | 6 | 2017 | 41 | 1.490 |
Why?
|
Carcinoma, Basal Cell | 10 | 2015 | 26 | 1.490 |
Why?
|
Cyclosporine | 11 | 2020 | 49 | 1.460 |
Why?
|
Infant | 28 | 2020 | 1076 | 1.440 |
Why?
|
Piperidines | 8 | 2018 | 125 | 1.420 |
Why?
|
Tacrolimus | 8 | 2018 | 64 | 1.400 |
Why?
|
Caregivers | 6 | 2019 | 112 | 1.400 |
Why?
|
Goals | 2 | 2020 | 37 | 1.390 |
Why?
|
Gels | 11 | 2017 | 32 | 1.390 |
Why?
|
Mohs Surgery | 9 | 2020 | 16 | 1.380 |
Why?
|
Sex Factors | 21 | 2020 | 674 | 1.380 |
Why?
|
Tuberculosis | 5 | 2020 | 15 | 1.370 |
Why?
|
Small Molecule Libraries | 3 | 2017 | 11 | 1.370 |
Why?
|
Interleukin-23 Subunit p19 | 2 | 2019 | 11 | 1.350 |
Why?
|
Hyperlipidemias | 3 | 2018 | 54 | 1.340 |
Why?
|
Fingers | 3 | 2019 | 64 | 1.340 |
Why?
|
Patient Selection | 9 | 2015 | 289 | 1.340 |
Why?
|
Recombinant Fusion Proteins | 10 | 2013 | 103 | 1.340 |
Why?
|
Registries | 8 | 2021 | 300 | 1.340 |
Why?
|
Triamcinolone | 5 | 2018 | 13 | 1.330 |
Why?
|
Ethnic Groups | 8 | 2020 | 480 | 1.330 |
Why?
|
Clindamycin | 4 | 2014 | 21 | 1.320 |
Why?
|
Salicylic Acid | 5 | 2013 | 6 | 1.300 |
Why?
|
Wound Healing | 7 | 2018 | 194 | 1.280 |
Why?
|
Cross-Sectional Studies | 28 | 2020 | 1522 | 1.270 |
Why?
|
Health Resources | 3 | 2018 | 33 | 1.260 |
Why?
|
Dermatitis | 9 | 2019 | 21 | 1.250 |
Why?
|
Arthritis, Rheumatoid | 3 | 2018 | 40 | 1.250 |
Why?
|
Drug Packaging | 3 | 2020 | 5 | 1.250 |
Why?
|
Behavior, Addictive | 4 | 2009 | 32 | 1.250 |
Why?
|
Lasers, Excimer | 4 | 2012 | 8 | 1.240 |
Why?
|
Delivery of Health Care | 8 | 2017 | 161 | 1.240 |
Why?
|
Carcinoma, Squamous Cell | 9 | 2015 | 154 | 1.220 |
Why?
|
Vitamin D | 8 | 2020 | 186 | 1.210 |
Why?
|
Animals | 27 | 2020 | 7694 | 1.210 |
Why?
|
Foot Dermatoses | 5 | 2009 | 9 | 1.190 |
Why?
|
Keratosis | 7 | 2016 | 23 | 1.190 |
Why?
|
Primary Health Care | 6 | 2017 | 221 | 1.170 |
Why?
|
Doxycycline | 4 | 2017 | 25 | 1.160 |
Why?
|
Dermatitis, Contact | 6 | 2014 | 11 | 1.160 |
Why?
|
Physicians | 9 | 2018 | 161 | 1.150 |
Why?
|
Antifungal Agents | 5 | 2015 | 39 | 1.150 |
Why?
|
Transients and Migrants | 17 | 2013 | 293 | 1.150 |
Why?
|
Dose-Response Relationship, Drug | 16 | 2019 | 675 | 1.150 |
Why?
|
Attitude of Health Personnel | 5 | 2014 | 182 | 1.140 |
Why?
|
Hypothyroidism | 2 | 2016 | 13 | 1.130 |
Why?
|
Patient Care Planning | 3 | 2020 | 58 | 1.130 |
Why?
|
Biomedical Research | 4 | 2019 | 169 | 1.110 |
Why?
|
Melanoma | 8 | 2017 | 165 | 1.110 |
Why?
|
Dermatitis, Occupational | 5 | 2019 | 10 | 1.100 |
Why?
|
Reminder Systems | 2 | 2018 | 22 | 1.100 |
Why?
|
Coronavirus Infections | 4 | 2020 | 113 | 1.100 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 118 | 1.090 |
Why?
|
Medicine | 7 | 2020 | 39 | 1.090 |
Why?
|
Ointments | 13 | 2020 | 24 | 1.080 |
Why?
|
Melanosis | 7 | 2010 | 15 | 1.070 |
Why?
|
Models, Economic | 8 | 2018 | 20 | 1.060 |
Why?
|
Emollients | 8 | 2017 | 11 | 1.050 |
Why?
|
Fluocinonide | 5 | 2019 | 11 | 1.050 |
Why?
|
Onychomycosis | 4 | 2019 | 8 | 1.040 |
Why?
|
Ivermectin | 4 | 2018 | 9 | 1.040 |
Why?
|
Insurance Coverage | 7 | 2017 | 75 | 1.030 |
Why?
|
Dicarboxylic Acids | 4 | 2017 | 10 | 1.020 |
Why?
|
Cardiovascular Diseases | 8 | 2018 | 1133 | 1.020 |
Why?
|
Hyperpigmentation | 4 | 2018 | 17 | 1.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2017 | 353 | 1.010 |
Why?
|
Protein Kinase Inhibitors | 6 | 2018 | 85 | 1.010 |
Why?
|
Contraceptives, Oral, Combined | 2 | 2017 | 6 | 1.010 |
Why?
|
Beauty Culture | 5 | 2009 | 7 | 1.010 |
Why?
|
Drug Compounding | 8 | 2019 | 37 | 1.000 |
Why?
|
Managed Care Programs | 8 | 2014 | 41 | 1.000 |
Why?
|
Hispanic Americans | 21 | 2014 | 949 | 0.990 |
Why?
|
Hospitalization | 11 | 2020 | 465 | 0.990 |
Why?
|
Photography | 4 | 2020 | 41 | 0.990 |
Why?
|
Prednisone | 4 | 2012 | 62 | 0.980 |
Why?
|
Telemedicine | 4 | 2021 | 99 | 0.980 |
Why?
|
Specialties, Surgical | 3 | 2013 | 27 | 0.970 |
Why?
|
Scalp | 5 | 2020 | 38 | 0.970 |
Why?
|
Placebo Effect | 4 | 2017 | 15 | 0.970 |
Why?
|
Off-Label Use | 6 | 2020 | 12 | 0.960 |
Why?
|
Tetracycline | 4 | 2014 | 12 | 0.960 |
Why?
|
Utilization Review | 2 | 2019 | 17 | 0.960 |
Why?
|
Cicatrix | 3 | 2015 | 38 | 0.960 |
Why?
|
Treatment Refusal | 4 | 2007 | 11 | 0.950 |
Why?
|
Hot Temperature | 5 | 2014 | 79 | 0.950 |
Why?
|
Nonprescription Drugs | 5 | 2015 | 21 | 0.950 |
Why?
|
Clinical Trials, Phase III as Topic | 7 | 2020 | 28 | 0.940 |
Why?
|
Allergens | 2 | 2019 | 18 | 0.940 |
Why?
|
Depressive Disorder | 3 | 2018 | 76 | 0.940 |
Why?
|
Combined Modality Therapy | 15 | 2019 | 567 | 0.940 |
Why?
|
Continental Population Groups | 4 | 2020 | 239 | 0.940 |
Why?
|
Health Services Accessibility | 5 | 2017 | 242 | 0.940 |
Why?
|
Health Promotion | 3 | 2018 | 242 | 0.940 |
Why?
|
Pharmaceutical Preparations | 2 | 2019 | 37 | 0.930 |
Why?
|
Risk | 4 | 2018 | 325 | 0.920 |
Why?
|
Medicaid | 9 | 2020 | 95 | 0.920 |
Why?
|
Interleukin-23 | 4 | 2019 | 22 | 0.910 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 2 | 2019 | 9 | 0.910 |
Why?
|
Pathology | 3 | 2009 | 19 | 0.900 |
Why?
|
Vasoconstriction | 4 | 2017 | 41 | 0.900 |
Why?
|
Risk Factors | 26 | 2021 | 3876 | 0.890 |
Why?
|
Follow-Up Studies | 20 | 2018 | 2296 | 0.890 |
Why?
|
Reimbursement, Incentive | 2 | 2015 | 11 | 0.890 |
Why?
|
Disease Management | 5 | 2018 | 131 | 0.890 |
Why?
|
Monitoring, Physiologic | 3 | 2020 | 77 | 0.880 |
Why?
|
Cost Control | 3 | 2020 | 18 | 0.880 |
Why?
|
Azetidines | 2 | 2020 | 10 | 0.880 |
Why?
|
Dermoscopy | 2 | 2013 | 12 | 0.880 |
Why?
|
Attitude to Health | 6 | 2019 | 167 | 0.870 |
Why?
|
Laser Therapy | 7 | 2019 | 55 | 0.870 |
Why?
|
Burns | 2 | 2014 | 102 | 0.870 |
Why?
|
Counseling | 3 | 2020 | 99 | 0.870 |
Why?
|
Sickness Impact Profile | 9 | 2015 | 37 | 0.860 |
Why?
|
Video Recording | 2 | 2013 | 57 | 0.860 |
Why?
|
Tetracyclines | 2 | 2019 | 2 | 0.850 |
Why?
|
Sulfonamides | 2 | 2020 | 67 | 0.850 |
Why?
|
Vitiligo | 3 | 2019 | 4 | 0.840 |
Why?
|
Research Design | 7 | 2015 | 313 | 0.840 |
Why?
|
Surgery, Plastic | 5 | 2013 | 27 | 0.830 |
Why?
|
Quality Assurance, Health Care | 3 | 2009 | 74 | 0.830 |
Why?
|
Ethics, Medical | 2 | 2020 | 21 | 0.830 |
Why?
|
Drugs, Generic | 5 | 2020 | 15 | 0.820 |
Why?
|
Vasoconstrictor Agents | 2 | 2019 | 62 | 0.810 |
Why?
|
Hypertension | 3 | 2018 | 972 | 0.810 |
Why?
|
Treatment Failure | 8 | 2018 | 171 | 0.810 |
Why?
|
Equipment and Supplies | 2 | 2020 | 16 | 0.800 |
Why?
|
Guidelines as Topic | 2 | 2020 | 48 | 0.800 |
Why?
|
Autoimmune Diseases | 3 | 2018 | 49 | 0.800 |
Why?
|
Petrolatum | 2 | 2020 | 4 | 0.800 |
Why?
|
Prescription Fees | 2 | 2016 | 6 | 0.800 |
Why?
|
Adolescent Behavior | 2 | 2020 | 61 | 0.800 |
Why?
|
Cryosurgery | 4 | 2015 | 21 | 0.790 |
Why?
|
United States Food and Drug Administration | 7 | 2019 | 48 | 0.790 |
Why?
|
Education, Distance | 1 | 2021 | 18 | 0.780 |
Why?
|
Pilot Projects | 11 | 2018 | 536 | 0.770 |
Why?
|
Budgets | 2 | 2018 | 10 | 0.770 |
Why?
|
Obesity | 9 | 2018 | 1164 | 0.770 |
Why?
|
Surgical Procedures, Operative | 5 | 2010 | 83 | 0.760 |
Why?
|
Self Concept | 5 | 2015 | 42 | 0.760 |
Why?
|
Clinical Clerkship | 1 | 2021 | 42 | 0.760 |
Why?
|
Therapies, Investigational | 1 | 2020 | 4 | 0.760 |
Why?
|
Antiviral Agents | 3 | 2020 | 110 | 0.760 |
Why?
|
Adrenergic alpha-Agonists | 2 | 2017 | 42 | 0.760 |
Why?
|
Tattooing | 2 | 2011 | 7 | 0.760 |
Why?
|
Inflammation | 4 | 2019 | 542 | 0.750 |
Why?
|
Specialization | 6 | 2017 | 32 | 0.750 |
Why?
|
Plant Extracts | 2 | 2018 | 61 | 0.750 |
Why?
|
Anti-Infective Agents, Local | 2 | 2020 | 15 | 0.740 |
Why?
|
Forehead | 1 | 2020 | 13 | 0.740 |
Why?
|
Sleep | 2 | 2013 | 93 | 0.740 |
Why?
|
Aerosols | 2 | 2020 | 14 | 0.740 |
Why?
|
Phobic Disorders | 1 | 2020 | 9 | 0.740 |
Why?
|
Incidence | 13 | 2021 | 1207 | 0.740 |
Why?
|
Gentian Violet | 1 | 2020 | 3 | 0.730 |
Why?
|
Immunotherapy | 2 | 2018 | 83 | 0.730 |
Why?
|
Professional Practice | 3 | 2011 | 24 | 0.730 |
Why?
|
Medication Errors | 4 | 2009 | 22 | 0.730 |
Why?
|
Warts | 1 | 2020 | 3 | 0.720 |
Why?
|
Injections, Intralesional | 1 | 2020 | 15 | 0.720 |
Why?
|
Back | 1 | 2020 | 4 | 0.720 |
Why?
|
Social Conformity | 1 | 2020 | 1 | 0.720 |
Why?
|
Baths | 1 | 2020 | 8 | 0.720 |
Why?
|
Cultural Diversity | 1 | 2020 | 22 | 0.710 |
Why?
|
Drug Delivery Systems | 3 | 2020 | 101 | 0.710 |
Why?
|
Impetigo | 2 | 2012 | 4 | 0.710 |
Why?
|
Affect | 3 | 2011 | 69 | 0.710 |
Why?
|
Infant, Newborn | 13 | 2020 | 681 | 0.700 |
Why?
|
Balsams | 1 | 2019 | 1 | 0.700 |
Why?
|
Electrical Equipment and Supplies | 1 | 2019 | 1 | 0.700 |
Why?
|
Job Application | 1 | 2019 | 6 | 0.700 |
Why?
|
Pigmentation Disorders | 3 | 2014 | 8 | 0.700 |
Why?
|
Books | 1 | 2019 | 3 | 0.700 |
Why?
|
Alcoholic Beverages | 1 | 2019 | 6 | 0.700 |
Why?
|
North Carolina | 23 | 2017 | 1520 | 0.700 |
Why?
|
Neuralgia, Postherpetic | 1 | 2019 | 6 | 0.700 |
Why?
|
Safety Management | 3 | 2010 | 36 | 0.700 |
Why?
|
Cost Savings | 5 | 2013 | 34 | 0.700 |
Why?
|
Patient Care | 3 | 2017 | 37 | 0.690 |
Why?
|
Leg Dermatoses | 1 | 2019 | 2 | 0.690 |
Why?
|
Multivariate Analysis | 14 | 2015 | 696 | 0.690 |
Why?
|
Skin Diseases, Genetic | 1 | 2019 | 4 | 0.690 |
Why?
|
Self Administration | 3 | 2010 | 303 | 0.680 |
Why?
|
Patients | 5 | 2013 | 47 | 0.670 |
Why?
|
Bonding, Human-Pet | 1 | 2019 | 1 | 0.670 |
Why?
|
Veterinarians | 1 | 2019 | 1 | 0.670 |
Why?
|
Animal Husbandry | 1 | 2019 | 7 | 0.670 |
Why?
|
Injections, Subcutaneous | 6 | 2019 | 38 | 0.670 |
Why?
|
Perception | 5 | 2018 | 98 | 0.670 |
Why?
|
Finger Joint | 1 | 2019 | 12 | 0.660 |
Why?
|
Skin Aging | 1 | 2019 | 8 | 0.660 |
Why?
|
Fish Oils | 1 | 2019 | 35 | 0.660 |
Why?
|
Family Practice | 6 | 2015 | 51 | 0.660 |
Why?
|
Electrocoagulation | 2 | 2016 | 12 | 0.660 |
Why?
|
Morgellons Disease | 1 | 2018 | 3 | 0.660 |
Why?
|
Wound Infection | 1 | 2018 | 12 | 0.660 |
Why?
|
Fees and Charges | 2 | 2016 | 14 | 0.660 |
Why?
|
Whole-Body Irradiation | 1 | 2019 | 50 | 0.660 |
Why?
|
Aortitis | 1 | 2018 | 1 | 0.660 |
Why?
|
Pharmacogenetics | 1 | 2018 | 36 | 0.660 |
Why?
|
Economics, Pharmaceutical | 4 | 2017 | 5 | 0.650 |
Why?
|
Income | 2 | 2021 | 60 | 0.650 |
Why?
|
Benchmarking | 4 | 2012 | 26 | 0.650 |
Why?
|
Chronic Disease | 12 | 2017 | 406 | 0.650 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2018 | 29 | 0.650 |
Why?
|
Hepatitis B | 1 | 2018 | 17 | 0.650 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 29 | 0.650 |
Why?
|
Antipsychotic Agents | 1 | 2018 | 28 | 0.650 |
Why?
|
Patient-Centered Care | 2 | 2012 | 74 | 0.650 |
Why?
|
Adaptation, Psychological | 2 | 2017 | 134 | 0.640 |
Why?
|
Public Opinion | 2 | 2018 | 19 | 0.640 |
Why?
|
Sick Leave | 1 | 2018 | 4 | 0.640 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2018 | 5 | 0.640 |
Why?
|
Education, Medical, Graduate | 3 | 2015 | 126 | 0.640 |
Why?
|
Prescriptions | 3 | 2015 | 12 | 0.640 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 31 | 0.640 |
Why?
|
Emergency Service, Hospital | 3 | 2016 | 463 | 0.630 |
Why?
|
Nails, Ingrown | 2 | 2015 | 2 | 0.630 |
Why?
|
Blood Donors | 1 | 2018 | 13 | 0.630 |
Why?
|
Tinea | 2 | 2016 | 4 | 0.630 |
Why?
|
Cytokines | 2 | 2017 | 262 | 0.630 |
Why?
|
Confidentiality | 1 | 2018 | 30 | 0.630 |
Why?
|
Porphyrins | 1 | 2018 | 29 | 0.630 |
Why?
|
Injections | 5 | 2019 | 65 | 0.630 |
Why?
|
Porphyria Cutanea Tarda | 1 | 2018 | 15 | 0.620 |
Why?
|
Health Services | 2 | 2017 | 39 | 0.620 |
Why?
|
Candidiasis, Chronic Mucocutaneous | 1 | 2017 | 1 | 0.620 |
Why?
|
Donor Selection | 1 | 2018 | 33 | 0.620 |
Why?
|
International Cooperation | 2 | 2020 | 28 | 0.620 |
Why?
|
Range of Motion, Articular | 1 | 2019 | 187 | 0.620 |
Why?
|
Efficiency | 4 | 2019 | 18 | 0.620 |
Why?
|
Caloric Restriction | 1 | 2019 | 96 | 0.610 |
Why?
|
Drug Resistance | 4 | 2018 | 42 | 0.610 |
Why?
|
Logistic Models | 10 | 2015 | 788 | 0.610 |
Why?
|
Janus Kinases | 3 | 2016 | 4 | 0.600 |
Why?
|
Alopecia Areata | 2 | 2015 | 16 | 0.600 |
Why?
|
Academic Medical Centers | 5 | 2019 | 160 | 0.600 |
Why?
|
Faculty, Medical | 2 | 2010 | 78 | 0.600 |
Why?
|
Drug Approval | 4 | 2019 | 10 | 0.590 |
Why?
|
Glioma | 1 | 2019 | 136 | 0.590 |
Why?
|
Medical Errors | 2 | 2010 | 38 | 0.590 |
Why?
|
Nevus | 2 | 2015 | 15 | 0.590 |
Why?
|
Health Behavior | 3 | 2015 | 229 | 0.590 |
Why?
|
Photochemotherapy | 2 | 2017 | 21 | 0.590 |
Why?
|
Agriculture | 7 | 2013 | 186 | 0.590 |
Why?
|
Alcohol Drinking | 2 | 2017 | 257 | 0.590 |
Why?
|
Receptors, Interleukin | 1 | 2017 | 16 | 0.590 |
Why?
|
Staphylococcus aureus | 2 | 2019 | 46 | 0.590 |
Why?
|
Liver Neoplasms | 1 | 2019 | 159 | 0.580 |
Why?
|
Residence Characteristics | 2 | 2017 | 190 | 0.580 |
Why?
|
Facial Neoplasms | 2 | 2008 | 9 | 0.580 |
Why?
|
Professional-Patient Relations | 1 | 2017 | 26 | 0.580 |
Why?
|
Sunlight | 6 | 2019 | 17 | 0.580 |
Why?
|
Parents | 3 | 2020 | 150 | 0.570 |
Why?
|
Electrodes | 2 | 2016 | 19 | 0.570 |
Why?
|
Cellulitis | 1 | 2016 | 11 | 0.570 |
Why?
|
Cohort Studies | 9 | 2018 | 1832 | 0.570 |
Why?
|
Abscess | 1 | 2016 | 26 | 0.570 |
Why?
|
Exanthema | 1 | 2016 | 21 | 0.570 |
Why?
|
Outpatients | 6 | 2016 | 58 | 0.560 |
Why?
|
Online Systems | 1 | 2016 | 13 | 0.560 |
Why?
|
Software | 2 | 2017 | 126 | 0.560 |
Why?
|
Pyrazoles | 2 | 2017 | 68 | 0.560 |
Why?
|
Zebrafish | 1 | 2016 | 23 | 0.560 |
Why?
|
Diagnostic Errors | 1 | 2016 | 46 | 0.560 |
Why?
|
Reproducibility of Results | 11 | 2020 | 779 | 0.560 |
Why?
|
Biomimetic Materials | 1 | 2016 | 16 | 0.560 |
Why?
|
Biopsy, Needle | 2 | 2018 | 98 | 0.550 |
Why?
|
Health Care Rationing | 2 | 2014 | 14 | 0.550 |
Why?
|
Electrosurgery | 3 | 2014 | 5 | 0.550 |
Why?
|
Accidents, Traffic | 1 | 2018 | 195 | 0.550 |
Why?
|
Skin Pigmentation | 5 | 2014 | 25 | 0.550 |
Why?
|
Interpersonal Relations | 4 | 2017 | 56 | 0.540 |
Why?
|
Cryotherapy | 3 | 2012 | 13 | 0.540 |
Why?
|
Abnormalities, Drug-Induced | 2 | 2006 | 5 | 0.540 |
Why?
|
Medical Records | 4 | 2013 | 77 | 0.540 |
Why?
|
Hydroquinones | 4 | 2014 | 6 | 0.540 |
Why?
|
African Americans | 8 | 2017 | 1443 | 0.530 |
Why?
|
Naltrexone | 2 | 2006 | 42 | 0.520 |
Why?
|
Empathy | 2 | 2013 | 19 | 0.520 |
Why?
|
Mothers | 2 | 2013 | 87 | 0.520 |
Why?
|
Body Surface Area | 3 | 2017 | 15 | 0.520 |
Why?
|
Spondylitis, Ankylosing | 1 | 2015 | 4 | 0.520 |
Why?
|
Occupational Diseases | 6 | 2014 | 81 | 0.510 |
Why?
|
Teratoma | 1 | 2015 | 10 | 0.510 |
Why?
|
Fee-for-Service Plans | 1 | 2015 | 12 | 0.510 |
Why?
|
Etretinate | 2 | 2013 | 2 | 0.510 |
Why?
|
Costs and Cost Analysis | 5 | 2016 | 100 | 0.510 |
Why?
|
European Continental Ancestry Group | 9 | 2017 | 1180 | 0.510 |
Why?
|
Precancerous Conditions | 3 | 2011 | 27 | 0.500 |
Why?
|
Diagnosis, Differential | 7 | 2018 | 525 | 0.500 |
Why?
|
Needs Assessment | 3 | 2014 | 78 | 0.500 |
Why?
|
Disease Models, Animal | 2 | 2016 | 1040 | 0.500 |
Why?
|
Urocanic Acid | 1 | 2014 | 1 | 0.500 |
Why?
|
Physical Examination | 3 | 2015 | 94 | 0.500 |
Why?
|
Splints | 1 | 2014 | 13 | 0.500 |
Why?
|
Lipoxins | 1 | 2014 | 2 | 0.500 |
Why?
|
Acrylates | 1 | 2014 | 1 | 0.500 |
Why?
|
Onycholysis | 1 | 2014 | 1 | 0.500 |
Why?
|
Age Distribution | 6 | 2020 | 210 | 0.500 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2020 | 17 | 0.500 |
Why?
|
Arthritis | 1 | 2015 | 40 | 0.490 |
Why?
|
Electronic Mail | 2 | 2017 | 18 | 0.490 |
Why?
|
Social Desirability | 1 | 2014 | 12 | 0.490 |
Why?
|
Parathyroid Neoplasms | 1 | 2014 | 7 | 0.490 |
Why?
|
Medically Underserved Area | 3 | 2013 | 23 | 0.490 |
Why?
|
Single-Blind Method | 4 | 2020 | 200 | 0.490 |
Why?
|
Antihypertensive Agents | 1 | 2017 | 362 | 0.490 |
Why?
|
Surgical Wound Infection | 2 | 2014 | 90 | 0.490 |
Why?
|
Antitubercular Agents | 1 | 2014 | 7 | 0.480 |
Why?
|
Electronic Health Records | 5 | 2018 | 158 | 0.480 |
Why?
|
Isoniazid | 1 | 2014 | 3 | 0.480 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2014 | 7 | 0.480 |
Why?
|
Quality Indicators, Health Care | 3 | 2015 | 62 | 0.480 |
Why?
|
Self Medication | 2 | 2011 | 6 | 0.480 |
Why?
|
Excipients | 1 | 2014 | 2 | 0.480 |
Why?
|
Erythromycin | 1 | 2014 | 7 | 0.480 |
Why?
|
Rural Health Services | 3 | 2009 | 30 | 0.480 |
Why?
|
Home Nursing | 3 | 2010 | 10 | 0.480 |
Why?
|
Adenoma | 1 | 2014 | 39 | 0.480 |
Why?
|
Anxiety | 7 | 2021 | 185 | 0.470 |
Why?
|
Contraceptives, Oral | 2 | 2012 | 22 | 0.470 |
Why?
|
Gynecomastia | 1 | 2014 | 2 | 0.470 |
Why?
|
Head and Neck Neoplasms | 3 | 2015 | 129 | 0.470 |
Why?
|
Webcasts as Topic | 2 | 2012 | 3 | 0.470 |
Why?
|
Scurvy | 1 | 2013 | 3 | 0.470 |
Why?
|
Case-Control Studies | 6 | 2020 | 911 | 0.470 |
Why?
|
Hidradenitis Suppurativa | 3 | 2019 | 9 | 0.460 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 44 | 0.460 |
Why?
|
Flutamide | 1 | 2013 | 6 | 0.460 |
Why?
|
Hydroxy Acids | 1 | 2013 | 2 | 0.460 |
Why?
|
Lupus Erythematosus, Systemic | 2 | 2014 | 148 | 0.460 |
Why?
|
HIV Infections | 1 | 2018 | 388 | 0.460 |
Why?
|
Folic Acid Deficiency | 1 | 2013 | 2 | 0.450 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 40 | 0.450 |
Why?
|
Folic Acid Antagonists | 1 | 2013 | 3 | 0.450 |
Why?
|
Herpes Labialis | 1 | 2013 | 1 | 0.450 |
Why?
|
Drug Eruptions | 1 | 2013 | 9 | 0.450 |
Why?
|
Transportation | 1 | 2013 | 13 | 0.450 |
Why?
|
Folic Acid | 1 | 2013 | 13 | 0.450 |
Why?
|
Breast | 1 | 2014 | 61 | 0.450 |
Why?
|
Drug Tolerance | 1 | 2013 | 35 | 0.450 |
Why?
|
Consensus | 4 | 2020 | 83 | 0.450 |
Why?
|
Clinical Competence | 5 | 2015 | 331 | 0.450 |
Why?
|
Dermatomycoses | 3 | 2009 | 7 | 0.450 |
Why?
|
Physician Assistants | 3 | 2010 | 42 | 0.450 |
Why?
|
Socioeconomic Factors | 6 | 2018 | 422 | 0.450 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 93 | 0.440 |
Why?
|
Health Surveys | 8 | 2019 | 202 | 0.440 |
Why?
|
Nevus, Sebaceous of Jadassohn | 1 | 2012 | 1 | 0.440 |
Why?
|
Mouth | 1 | 2013 | 25 | 0.440 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2013 | 46 | 0.430 |
Why?
|
Staphylococcal Skin Infections | 1 | 2012 | 4 | 0.430 |
Why?
|
Health Services Research | 3 | 2010 | 82 | 0.430 |
Why?
|
Disease Progression | 4 | 2018 | 618 | 0.430 |
Why?
|
Patch Tests | 4 | 2010 | 8 | 0.430 |
Why?
|
Progestins | 1 | 2012 | 21 | 0.420 |
Why?
|
Decision Making | 2 | 2019 | 205 | 0.420 |
Why?
|
Telephone | 4 | 2018 | 59 | 0.420 |
Why?
|
Hydrocortisone | 2 | 2011 | 61 | 0.420 |
Why?
|
Employment | 2 | 2018 | 49 | 0.420 |
Why?
|
Antimetabolites | 1 | 2012 | 11 | 0.420 |
Why?
|
Cosmetics | 3 | 2010 | 11 | 0.420 |
Why?
|
Arthrodermataceae | 2 | 2009 | 3 | 0.410 |
Why?
|
Imaging, Three-Dimensional | 1 | 2013 | 133 | 0.410 |
Why?
|
Organ Transplantation | 1 | 2012 | 69 | 0.410 |
Why?
|
Drug Resistance, Bacterial | 5 | 2014 | 42 | 0.400 |
Why?
|
Data Collection | 6 | 2014 | 185 | 0.400 |
Why?
|
Practice Management, Medical | 2 | 2013 | 8 | 0.400 |
Why?
|
Fluocinolone Acetonide | 2 | 2012 | 7 | 0.400 |
Why?
|
Choice Behavior | 3 | 2019 | 86 | 0.400 |
Why?
|
Demyelinating Diseases | 1 | 2011 | 10 | 0.400 |
Why?
|
Self-Examination | 1 | 2011 | 1 | 0.400 |
Why?
|
Self Efficacy | 3 | 2017 | 78 | 0.400 |
Why?
|
Propionibacterium acnes | 4 | 2014 | 4 | 0.390 |
Why?
|
Health Status | 3 | 2011 | 402 | 0.390 |
Why?
|
Pityriasis Rubra Pilaris | 1 | 2011 | 1 | 0.390 |
Why?
|
Information Dissemination | 2 | 2009 | 51 | 0.390 |
Why?
|
Foundations | 2 | 2008 | 8 | 0.390 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 244 | 0.390 |
Why?
|
Regression Analysis | 6 | 2017 | 296 | 0.390 |
Why?
|
Molluscum Contagiosum | 2 | 2015 | 3 | 0.390 |
Why?
|
Appointments and Schedules | 2 | 2020 | 21 | 0.390 |
Why?
|
Estrogens | 1 | 2012 | 174 | 0.390 |
Why?
|
Zinc | 2 | 2019 | 32 | 0.380 |
Why?
|
Computer Peripherals | 1 | 2010 | 1 | 0.380 |
Why?
|
Friction | 1 | 2010 | 4 | 0.380 |
Why?
|
Diet | 1 | 2013 | 384 | 0.380 |
Why?
|
Odds Ratio | 6 | 2017 | 480 | 0.380 |
Why?
|
Photosensitizing Agents | 3 | 2010 | 23 | 0.380 |
Why?
|
Clotrimazole | 3 | 2007 | 4 | 0.380 |
Why?
|
Educational Status | 4 | 2020 | 177 | 0.380 |
Why?
|
Eyeglasses | 1 | 2010 | 3 | 0.380 |
Why?
|
Antidepressive Agents | 2 | 2014 | 77 | 0.370 |
Why?
|
Chromium | 1 | 2010 | 1 | 0.370 |
Why?
|
Nickel | 1 | 2010 | 2 | 0.370 |
Why?
|
Linear Models | 4 | 2019 | 454 | 0.370 |
Why?
|
Risk-Taking | 2 | 2009 | 97 | 0.370 |
Why?
|
Health Services Misuse | 1 | 2010 | 7 | 0.370 |
Why?
|
Frozen Sections | 1 | 2010 | 18 | 0.370 |
Why?
|
Desonide | 1 | 2010 | 1 | 0.370 |
Why?
|
Pharmaceutical Services | 1 | 2010 | 6 | 0.370 |
Why?
|
Pregnancy | 9 | 2019 | 1010 | 0.370 |
Why?
|
Life Style | 1 | 2013 | 404 | 0.360 |
Why?
|
Vitamin E | 1 | 2010 | 23 | 0.360 |
Why?
|
Prospective Studies | 7 | 2018 | 2274 | 0.360 |
Why?
|
Publications | 1 | 2010 | 9 | 0.360 |
Why?
|
Ear Cartilage | 1 | 2010 | 12 | 0.360 |
Why?
|
Patient Participation | 2 | 2014 | 81 | 0.360 |
Why?
|
Algorithms | 6 | 2015 | 497 | 0.360 |
Why?
|
Medically Uninsured | 1 | 2010 | 32 | 0.360 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2014 | 49 | 0.360 |
Why?
|
Textiles | 1 | 2009 | 1 | 0.360 |
Why?
|
Clothing | 1 | 2009 | 5 | 0.360 |
Why?
|
Social Marketing | 1 | 2010 | 15 | 0.350 |
Why?
|
Cartilage Diseases | 1 | 2010 | 21 | 0.350 |
Why?
|
Financing, Personal | 2 | 2014 | 6 | 0.350 |
Why?
|
Marketing | 1 | 2010 | 24 | 0.350 |
Why?
|
Communicable Diseases | 1 | 2009 | 21 | 0.350 |
Why?
|
Health Care Reform | 1 | 2010 | 43 | 0.340 |
Why?
|
Cost Sharing | 2 | 2006 | 10 | 0.340 |
Why?
|
Data Interpretation, Statistical | 2 | 2013 | 110 | 0.340 |
Why?
|
Mandatory Reporting | 3 | 2006 | 7 | 0.340 |
Why?
|
Dermatitis, Perioral | 1 | 2009 | 1 | 0.340 |
Why?
|
Education, Medical | 1 | 2010 | 70 | 0.340 |
Why?
|
Burnout, Professional | 2 | 2021 | 50 | 0.340 |
Why?
|
General Surgery | 3 | 2014 | 85 | 0.340 |
Why?
|
Risk Management | 2 | 2006 | 29 | 0.340 |
Why?
|
Insurance Carriers | 1 | 2009 | 18 | 0.340 |
Why?
|
Neoplasms | 3 | 2017 | 695 | 0.340 |
Why?
|
Elastic Tissue | 1 | 2009 | 2 | 0.330 |
Why?
|
Triage | 2 | 2010 | 72 | 0.330 |
Why?
|
Radio Waves | 1 | 2009 | 8 | 0.330 |
Why?
|
Physicians' Offices | 3 | 2005 | 10 | 0.330 |
Why?
|
Narcotic Antagonists | 2 | 2006 | 59 | 0.330 |
Why?
|
Sirolimus | 1 | 2009 | 34 | 0.330 |
Why?
|
Pamphlets | 2 | 2007 | 5 | 0.330 |
Why?
|
Social Support | 3 | 2017 | 180 | 0.320 |
Why?
|
Language | 3 | 2007 | 45 | 0.320 |
Why?
|
Placebos | 3 | 2020 | 66 | 0.320 |
Why?
|
Mass Screening | 3 | 2017 | 263 | 0.320 |
Why?
|
Fibromyalgia | 1 | 2009 | 25 | 0.320 |
Why?
|
Fluocortolone | 1 | 2008 | 1 | 0.320 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 1428 | 0.320 |
Why?
|
Interleukin-12 | 2 | 2008 | 30 | 0.320 |
Why?
|
Guideline Adherence | 3 | 2015 | 122 | 0.320 |
Why?
|
Internal Medicine | 4 | 2015 | 54 | 0.320 |
Why?
|
Multicenter Studies as Topic | 3 | 2019 | 102 | 0.310 |
Why?
|
Hand | 2 | 2019 | 67 | 0.310 |
Why?
|
Crohn Disease | 2 | 2019 | 26 | 0.310 |
Why?
|
Selection Bias | 1 | 2008 | 14 | 0.310 |
Why?
|
Colitis, Ulcerative | 2 | 2018 | 22 | 0.310 |
Why?
|
Safety | 5 | 2011 | 78 | 0.310 |
Why?
|
Healthcare Disparities | 1 | 2010 | 166 | 0.310 |
Why?
|
Histamine Antagonists | 3 | 2018 | 5 | 0.310 |
Why?
|
Occupational Exposure | 5 | 2009 | 238 | 0.310 |
Why?
|
Social Problems | 1 | 2007 | 2 | 0.310 |
Why?
|
Interleukin-12 Subunit p40 | 1 | 2007 | 3 | 0.300 |
Why?
|
Internationality | 1 | 2007 | 22 | 0.300 |
Why?
|
Quality-Adjusted Life Years | 3 | 2017 | 30 | 0.300 |
Why?
|
Interviews as Topic | 6 | 2017 | 263 | 0.300 |
Why?
|
Asian Continental Ancestry Group | 3 | 2014 | 111 | 0.300 |
Why?
|
Episode of Care | 2 | 2004 | 5 | 0.300 |
Why?
|
Sexually Transmitted Diseases | 1 | 2008 | 42 | 0.300 |
Why?
|
Substance-Related Disorders | 1 | 2008 | 124 | 0.290 |
Why?
|
Pregnancy Outcome | 2 | 2018 | 91 | 0.290 |
Why?
|
Interleukins | 2 | 2017 | 17 | 0.290 |
Why?
|
Absenteeism | 3 | 2018 | 11 | 0.290 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2007 | 6 | 0.290 |
Why?
|
Career Choice | 1 | 2007 | 41 | 0.290 |
Why?
|
Sleep Apnea Syndromes | 2 | 2017 | 30 | 0.280 |
Why?
|
Forms and Records Control | 1 | 2006 | 7 | 0.280 |
Why?
|
Fellowships and Scholarships | 1 | 2007 | 53 | 0.280 |
Why?
|
Personality | 3 | 2014 | 16 | 0.280 |
Why?
|
Electronics | 1 | 2006 | 14 | 0.280 |
Why?
|
Tachyphylaxis | 1 | 2006 | 1 | 0.280 |
Why?
|
beta-Endorphin | 1 | 2006 | 2 | 0.280 |
Why?
|
Multiple Sclerosis | 1 | 2007 | 61 | 0.270 |
Why?
|
Women | 1 | 2006 | 11 | 0.270 |
Why?
|
Evaluation Studies as Topic | 2 | 2016 | 48 | 0.270 |
Why?
|
Seasons | 4 | 2017 | 86 | 0.270 |
Why?
|
Surgicenters | 2 | 2004 | 3 | 0.270 |
Why?
|
Anti-Allergic Agents | 2 | 2017 | 7 | 0.260 |
Why?
|
Reconstructive Surgical Procedures | 2 | 2007 | 199 | 0.260 |
Why?
|
Health Services for the Aged | 2 | 2007 | 28 | 0.260 |
Why?
|
Carcinoma | 1 | 2006 | 93 | 0.260 |
Why?
|
Europe | 3 | 2015 | 83 | 0.260 |
Why?
|
Insurance Benefits | 1 | 2005 | 5 | 0.260 |
Why?
|
Acne Keloid | 1 | 2005 | 2 | 0.260 |
Why?
|
Social Behavior | 1 | 2006 | 65 | 0.260 |
Why?
|
Insurance Claim Review | 2 | 2019 | 28 | 0.260 |
Why?
|
Withholding Treatment | 2 | 2018 | 12 | 0.260 |
Why?
|
Narcotics | 1 | 2005 | 19 | 0.260 |
Why?
|
Heliotherapy | 1 | 2005 | 3 | 0.250 |
Why?
|
Complementary Therapies | 2 | 2017 | 79 | 0.250 |
Why?
|
Sensitivity and Specificity | 3 | 2013 | 600 | 0.250 |
Why?
|
Hospital Charges | 1 | 2005 | 15 | 0.250 |
Why?
|
Tinea Pedis | 2 | 2015 | 5 | 0.250 |
Why?
|
Relaxation | 2 | 2019 | 9 | 0.250 |
Why?
|
Rheumatology | 3 | 2020 | 9 | 0.250 |
Why?
|
Fear | 2 | 2019 | 46 | 0.250 |
Why?
|
Sex Distribution | 3 | 2017 | 201 | 0.250 |
Why?
|
Automobiles | 2 | 2014 | 15 | 0.240 |
Why?
|
Dietary Supplements | 2 | 2019 | 184 | 0.240 |
Why?
|
Age of Onset | 3 | 2020 | 100 | 0.240 |
Why?
|
Lupus Erythematosus, Cutaneous | 2 | 2018 | 13 | 0.240 |
Why?
|
Bioterrorism | 1 | 2003 | 6 | 0.230 |
Why?
|
Meat-Packing Industry | 2 | 2014 | 8 | 0.230 |
Why?
|
Early Diagnosis | 2 | 2017 | 64 | 0.230 |
Why?
|
Itraconazole | 1 | 2003 | 6 | 0.230 |
Why?
|
Iran | 2 | 2013 | 4 | 0.230 |
Why?
|
Organometallic Compounds | 1 | 2003 | 25 | 0.230 |
Why?
|
Disclosure | 1 | 2003 | 39 | 0.230 |
Why?
|
Insurance Claim Reporting | 1 | 2003 | 3 | 0.220 |
Why?
|
Current Procedural Terminology | 1 | 2003 | 4 | 0.220 |
Why?
|
Program Development | 2 | 2018 | 97 | 0.220 |
Why?
|
Pyridines | 1 | 2003 | 81 | 0.220 |
Why?
|
Tonsillitis | 1 | 2003 | 5 | 0.220 |
Why?
|
Referral and Consultation | 3 | 2011 | 140 | 0.220 |
Why?
|
Occupational Health | 3 | 2015 | 82 | 0.220 |
Why?
|
Prognosis | 6 | 2019 | 1523 | 0.220 |
Why?
|
Directive Counseling | 1 | 2002 | 18 | 0.220 |
Why?
|
Qualitative Research | 3 | 2018 | 159 | 0.220 |
Why?
|
Pregnancy Complications | 2 | 2009 | 107 | 0.220 |
Why?
|
T-Lymphocytes | 2 | 2014 | 128 | 0.220 |
Why?
|
Aminoquinolines | 2 | 2015 | 16 | 0.210 |
Why?
|
Demography | 2 | 2020 | 109 | 0.210 |
Why?
|
Analysis of Variance | 4 | 2020 | 470 | 0.210 |
Why?
|
Nausea | 1 | 2002 | 54 | 0.210 |
Why?
|
Drugs, Investigational | 2 | 2020 | 7 | 0.210 |
Why?
|
Staphylococcal Infections | 1 | 2003 | 63 | 0.210 |
Why?
|
Diabetes Mellitus | 3 | 2015 | 410 | 0.210 |
Why?
|
Hypnotics and Sedatives | 1 | 2002 | 29 | 0.210 |
Why?
|
Food-Processing Industry | 3 | 2013 | 40 | 0.200 |
Why?
|
Drug Administration Routes | 3 | 2012 | 12 | 0.200 |
Why?
|
Equipment Design | 3 | 2014 | 172 | 0.200 |
Why?
|
Mice, Knockout | 2 | 2017 | 449 | 0.200 |
Why?
|
Emigrants and Immigrants | 3 | 2014 | 250 | 0.200 |
Why?
|
Dosage Forms | 2 | 2012 | 4 | 0.190 |
Why?
|
Solutions | 2 | 2016 | 36 | 0.190 |
Why?
|
Diterpenes | 1 | 2021 | 20 | 0.190 |
Why?
|
Psychometrics | 4 | 2015 | 137 | 0.190 |
Why?
|
Models, Econometric | 2 | 2017 | 8 | 0.190 |
Why?
|
History, 21st Century | 2 | 2020 | 61 | 0.190 |
Why?
|
Mental Disorders | 1 | 2002 | 119 | 0.190 |
Why?
|
History, 20th Century | 2 | 2020 | 76 | 0.190 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 6 | 0.190 |
Why?
|
Liver | 2 | 2016 | 486 | 0.190 |
Why?
|
Mice | 4 | 2017 | 2524 | 0.190 |
Why?
|
Societies, Medical | 3 | 2019 | 165 | 0.180 |
Why?
|
Postoperative Care | 2 | 2018 | 78 | 0.180 |
Why?
|
Lichen Sclerosus et Atrophicus | 1 | 2020 | 9 | 0.180 |
Why?
|
Employee Retirement Income Security Act | 1 | 2020 | 5 | 0.180 |
Why?
|
Face | 2 | 2017 | 30 | 0.180 |
Why?
|
Tuberculin | 1 | 2020 | 1 | 0.180 |
Why?
|
Pharmacy | 1 | 2020 | 2 | 0.180 |
Why?
|
Education, Medical, Undergraduate | 1 | 2021 | 88 | 0.180 |
Why?
|
Republic of Korea | 1 | 2020 | 12 | 0.180 |
Why?
|
Aminolevulinic Acid | 1 | 2020 | 9 | 0.180 |
Why?
|
Japan | 1 | 2020 | 17 | 0.180 |
Why?
|
Steroids | 1 | 2020 | 38 | 0.180 |
Why?
|
Mycobacterium | 1 | 2020 | 3 | 0.180 |
Why?
|
Bacterial Vaccines | 1 | 2020 | 8 | 0.180 |
Why?
|
Interdisciplinary Communication | 2 | 2013 | 58 | 0.180 |
Why?
|
Pain Measurement | 3 | 2018 | 370 | 0.180 |
Why?
|
Communicable Disease Control | 1 | 2020 | 15 | 0.180 |
Why?
|
BCG Vaccine | 1 | 2020 | 8 | 0.180 |
Why?
|
Journal Impact Factor | 1 | 2020 | 11 | 0.180 |
Why?
|
China | 1 | 2020 | 50 | 0.180 |
Why?
|
Drug Synergism | 1 | 2020 | 71 | 0.180 |
Why?
|
Blood Cell Count | 1 | 2020 | 28 | 0.180 |
Why?
|
Sampling Studies | 3 | 2009 | 43 | 0.180 |
Why?
|
Informed Consent | 1 | 2020 | 56 | 0.180 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 87 | 0.180 |
Why?
|
Neurodermatitis | 1 | 2019 | 3 | 0.180 |
Why?
|
Metabolome | 1 | 2020 | 36 | 0.180 |
Why?
|
Interferon-alpha | 1 | 2020 | 71 | 0.180 |
Why?
|
Congresses as Topic | 2 | 2012 | 39 | 0.170 |
Why?
|
Ficusin | 3 | 2010 | 5 | 0.170 |
Why?
|
Thorax | 1 | 2019 | 29 | 0.170 |
Why?
|
Authorship | 1 | 2019 | 9 | 0.170 |
Why?
|
Unnecessary Procedures | 1 | 2019 | 16 | 0.170 |
Why?
|
Statistics, Nonparametric | 2 | 2010 | 133 | 0.170 |
Why?
|
Students, Medical | 1 | 2021 | 131 | 0.170 |
Why?
|
Clinical Protocols | 2 | 2011 | 100 | 0.170 |
Why?
|
Random Allocation | 1 | 2020 | 220 | 0.170 |
Why?
|
Women's Health | 1 | 2021 | 235 | 0.170 |
Why?
|
Patient Care Team | 2 | 2010 | 131 | 0.170 |
Why?
|
Arm | 1 | 2019 | 36 | 0.170 |
Why?
|
Herpes Zoster Vaccine | 1 | 2019 | 4 | 0.170 |
Why?
|
Diet, Gluten-Free | 1 | 2019 | 3 | 0.170 |
Why?
|
Selenium | 1 | 2019 | 4 | 0.170 |
Why?
|
Malassezia | 1 | 2019 | 1 | 0.170 |
Why?
|
Work Schedule Tolerance | 1 | 2019 | 10 | 0.170 |
Why?
|
Herpes Zoster | 1 | 2019 | 10 | 0.170 |
Why?
|
Periodontitis | 1 | 2019 | 9 | 0.170 |
Why?
|
Croton | 1 | 2018 | 2 | 0.170 |
Why?
|
Hyperhidrosis | 1 | 2019 | 5 | 0.170 |
Why?
|
Candida albicans | 1 | 2019 | 12 | 0.170 |
Why?
|
Paternal Exposure | 1 | 2018 | 1 | 0.170 |
Why?
|
Streptococcus pyogenes | 1 | 2019 | 16 | 0.170 |
Why?
|
Probiotics | 1 | 2019 | 10 | 0.170 |
Why?
|
Glossitis, Benign Migratory | 1 | 2018 | 2 | 0.170 |
Why?
|
Risperidone | 1 | 2018 | 3 | 0.170 |
Why?
|
Databases as Topic | 1 | 2018 | 23 | 0.170 |
Why?
|
Trifluoperazine | 1 | 2018 | 4 | 0.170 |
Why?
|
Fatigue | 2 | 2009 | 85 | 0.170 |
Why?
|
Population Surveillance | 3 | 2010 | 124 | 0.170 |
Why?
|
Maternal Exposure | 1 | 2018 | 13 | 0.160 |
Why?
|
CD4 Lymphocyte Count | 1 | 2018 | 32 | 0.160 |
Why?
|
Virus Activation | 1 | 2018 | 7 | 0.160 |
Why?
|
Immune Tolerance | 1 | 2019 | 73 | 0.160 |
Why?
|
Red Cross | 1 | 2018 | 2 | 0.160 |
Why?
|
Primates | 1 | 2019 | 111 | 0.160 |
Why?
|
Asthma | 2 | 2015 | 438 | 0.160 |
Why?
|
World Health Organization | 1 | 2018 | 15 | 0.160 |
Why?
|
Skin Absorption | 3 | 2009 | 9 | 0.160 |
Why?
|
Antiparasitic Agents | 1 | 2018 | 6 | 0.160 |
Why?
|
Computer-Assisted Instruction | 1 | 2018 | 24 | 0.160 |
Why?
|
Fees, Pharmaceutical | 1 | 2018 | 2 | 0.160 |
Why?
|
Models, Organizational | 1 | 2018 | 17 | 0.160 |
Why?
|
Expert Testimony | 1 | 2018 | 11 | 0.160 |
Why?
|
Rhinophyma | 1 | 2017 | 2 | 0.160 |
Why?
|
Adamantane | 1 | 2017 | 3 | 0.160 |
Why?
|
Postoperative Complications | 4 | 2014 | 788 | 0.160 |
Why?
|
Lidocaine | 1 | 2018 | 18 | 0.150 |
Why?
|
Self-Help Groups | 1 | 2017 | 11 | 0.150 |
Why?
|
Niacinamide | 1 | 2017 | 8 | 0.150 |
Why?
|
Internal-External Control | 1 | 2017 | 17 | 0.150 |
Why?
|
Epinephrine | 1 | 2018 | 40 | 0.150 |
Why?
|
Keratinocytes | 2 | 2015 | 30 | 0.150 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 33 | 0.150 |
Why?
|
Social Perception | 1 | 2017 | 25 | 0.150 |
Why?
|
Information Services | 2 | 2009 | 15 | 0.150 |
Why?
|
Genes, Essential | 1 | 2017 | 4 | 0.150 |
Why?
|
Esophageal Neoplasms | 1 | 2017 | 35 | 0.150 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2017 | 19 | 0.150 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 43 | 0.150 |
Why?
|
Pituitary-Adrenal System | 1 | 2017 | 24 | 0.150 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2017 | 36 | 0.150 |
Why?
|
Videodisc Recording | 1 | 2017 | 4 | 0.150 |
Why?
|
Longitudinal Studies | 7 | 2009 | 786 | 0.150 |
Why?
|
Markov Chains | 1 | 2017 | 29 | 0.150 |
Why?
|
Tobacco | 2 | 2008 | 57 | 0.150 |
Why?
|
Anesthetics, Local | 1 | 2018 | 79 | 0.150 |
Why?
|
Coronary Disease | 1 | 2018 | 215 | 0.150 |
Why?
|
Substance Withdrawal Syndrome | 2 | 2009 | 61 | 0.150 |
Why?
|
Patient Advocacy | 2 | 2008 | 13 | 0.140 |
Why?
|
Lentigo | 2 | 2008 | 4 | 0.140 |
Why?
|
Immunoglobulin E | 1 | 2017 | 50 | 0.140 |
Why?
|
Journalism, Medical | 1 | 2016 | 2 | 0.140 |
Why?
|
Antineoplastic Agents | 2 | 2014 | 611 | 0.140 |
Why?
|
African Continental Ancestry Group | 4 | 2011 | 364 | 0.140 |
Why?
|
Quality Control | 1 | 2016 | 43 | 0.140 |
Why?
|
Workers' Compensation | 2 | 2006 | 3 | 0.140 |
Why?
|
Cattle | 1 | 2016 | 101 | 0.130 |
Why?
|
Th2 Cells | 1 | 2015 | 15 | 0.130 |
Why?
|
Minoxidil | 1 | 2015 | 6 | 0.130 |
Why?
|
Interleukin-4 | 1 | 2015 | 22 | 0.130 |
Why?
|
Moving and Lifting Patients | 1 | 2015 | 1 | 0.130 |
Why?
|
Probability | 4 | 2009 | 160 | 0.130 |
Why?
|
Interleukin-13 | 1 | 2015 | 33 | 0.130 |
Why?
|
Electronic Prescribing | 1 | 2015 | 2 | 0.130 |
Why?
|
Health Education | 2 | 2007 | 157 | 0.130 |
Why?
|
Vasodilator Agents | 1 | 2015 | 57 | 0.130 |
Why?
|
Botulinum Toxins | 1 | 2015 | 37 | 0.130 |
Why?
|
Florida | 2 | 2005 | 37 | 0.130 |
Why?
|
Canada | 2 | 2013 | 56 | 0.130 |
Why?
|
Antibodies | 1 | 2015 | 57 | 0.130 |
Why?
|
Emergency Medicine | 1 | 2016 | 120 | 0.130 |
Why?
|
Ulcer | 1 | 2014 | 3 | 0.130 |
Why?
|
Occlusive Dressings | 1 | 2014 | 10 | 0.130 |
Why?
|
Radiotherapy | 1 | 2015 | 82 | 0.130 |
Why?
|
Suspensions | 1 | 2014 | 2 | 0.130 |
Why?
|
Medical Informatics | 2 | 2007 | 27 | 0.130 |
Why?
|
Cyanoacrylates | 1 | 2014 | 2 | 0.130 |
Why?
|
Teaching | 1 | 2015 | 62 | 0.130 |
Why?
|
Hospital Costs | 1 | 2015 | 38 | 0.130 |
Why?
|
Toes | 1 | 2014 | 16 | 0.130 |
Why?
|
Musculoskeletal Diseases | 1 | 2015 | 38 | 0.130 |
Why?
|
Oceanic Ancestry Group | 1 | 2014 | 7 | 0.120 |
Why?
|
Thigh | 1 | 2014 | 42 | 0.120 |
Why?
|
Antigens, CD19 | 1 | 2014 | 9 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 1 | 2014 | 12 | 0.120 |
Why?
|
Lymphoma, B-Cell | 1 | 2014 | 11 | 0.120 |
Why?
|
Quinoxalines | 1 | 2014 | 13 | 0.120 |
Why?
|
Hypericum | 1 | 2014 | 2 | 0.120 |
Why?
|
Herb-Drug Interactions | 1 | 2014 | 2 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2014 | 27 | 0.120 |
Why?
|
Minocycline | 1 | 2014 | 11 | 0.120 |
Why?
|
Education, Medical, Continuing | 3 | 2014 | 57 | 0.120 |
Why?
|
Antibiotic Prophylaxis | 1 | 2014 | 38 | 0.120 |
Why?
|
Pancytopenia | 1 | 2014 | 3 | 0.120 |
Why?
|
Leukemia, Lymphoid | 1 | 2014 | 3 | 0.120 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 16 | 0.120 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2014 | 10 | 0.120 |
Why?
|
Resource Allocation | 1 | 2014 | 10 | 0.120 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2014 | 10 | 0.120 |
Why?
|
Single Person | 1 | 2014 | 3 | 0.120 |
Why?
|
Unemployment | 1 | 2014 | 4 | 0.120 |
Why?
|
Phytotherapy | 1 | 2014 | 38 | 0.120 |
Why?
|
Medical Staff | 1 | 2014 | 1 | 0.120 |
Why?
|
Tissue Distribution | 1 | 2014 | 62 | 0.120 |
Why?
|
Sarcomeres | 1 | 2014 | 3 | 0.120 |
Why?
|
NADPH Dehydrogenase | 1 | 2014 | 2 | 0.120 |
Why?
|
Drug Interactions | 1 | 2014 | 83 | 0.120 |
Why?
|
Cyclic AMP | 1 | 2014 | 47 | 0.120 |
Why?
|
rho GTP-Binding Proteins | 1 | 2014 | 10 | 0.120 |
Why?
|
Remission Induction | 2 | 2005 | 84 | 0.120 |
Why?
|
Actigraphy | 1 | 2014 | 13 | 0.120 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 35 | 0.120 |
Why?
|
Health Personnel | 1 | 2015 | 121 | 0.120 |
Why?
|
Mental Recall | 1 | 2014 | 51 | 0.120 |
Why?
|
Polysomnography | 1 | 2014 | 40 | 0.120 |
Why?
|
Triamcinolone Acetonide | 1 | 2013 | 4 | 0.120 |
Why?
|
Microfilament Proteins | 1 | 2014 | 35 | 0.120 |
Why?
|
Terminology as Topic | 2 | 2005 | 65 | 0.120 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2014 | 73 | 0.110 |
Why?
|
Muscle Development | 1 | 2014 | 48 | 0.110 |
Why?
|
Gasoline | 1 | 2013 | 1 | 0.110 |
Why?
|
Lighting | 1 | 2013 | 4 | 0.110 |
Why?
|
Biotechnology | 1 | 2013 | 6 | 0.110 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2013 | 4 | 0.110 |
Why?
|
Feedback | 1 | 2013 | 44 | 0.110 |
Why?
|
Osteoporosis | 1 | 2014 | 57 | 0.110 |
Why?
|
Acyclovir | 1 | 2013 | 13 | 0.110 |
Why?
|
Valine | 1 | 2013 | 17 | 0.110 |
Why?
|
Medical Waste Disposal | 1 | 2013 | 2 | 0.110 |
Why?
|
Herpes Simplex | 1 | 2013 | 14 | 0.110 |
Why?
|
Keloid | 1 | 2013 | 8 | 0.110 |
Why?
|
Needles | 1 | 2013 | 31 | 0.110 |
Why?
|
Ketoconazole | 1 | 2013 | 5 | 0.110 |
Why?
|
Dermatitis, Seborrheic | 1 | 2013 | 4 | 0.110 |
Why?
|
Vitamins | 1 | 2013 | 68 | 0.110 |
Why?
|
Equipment Failure Analysis | 1 | 2013 | 43 | 0.110 |
Why?
|
International Classification of Diseases | 1 | 2013 | 26 | 0.110 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 9 | 0.110 |
Why?
|
Sarcoma, Kaposi | 1 | 2012 | 8 | 0.110 |
Why?
|
Otolaryngology | 1 | 2013 | 18 | 0.110 |
Why?
|
Culture | 1 | 2012 | 41 | 0.110 |
Why?
|
Carcinoma in Situ | 1 | 2012 | 14 | 0.110 |
Why?
|
Myocardium | 1 | 2014 | 196 | 0.110 |
Why?
|
Cumulative Trauma Disorders | 1 | 2012 | 13 | 0.110 |
Why?
|
Fibroma | 1 | 2012 | 10 | 0.110 |
Why?
|
Image Enhancement | 1 | 2013 | 75 | 0.110 |
Why?
|
Housing | 1 | 2013 | 64 | 0.110 |
Why?
|
Methylprednisolone | 1 | 2012 | 13 | 0.100 |
Why?
|
Mexico | 3 | 2007 | 69 | 0.100 |
Why?
|
Controlled Clinical Trials as Topic | 2 | 2012 | 11 | 0.100 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 2 | 2018 | 36 | 0.100 |
Why?
|
Immunosuppression | 1 | 2012 | 121 | 0.100 |
Why?
|
Confidence Intervals | 2 | 2010 | 150 | 0.100 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 759 | 0.100 |
Why?
|
Fractures, Bone | 1 | 2014 | 157 | 0.100 |
Why?
|
Hypercholesterolemia | 1 | 2013 | 65 | 0.100 |
Why?
|
Liver Function Tests | 1 | 2011 | 22 | 0.100 |
Why?
|
Puberty, Precocious | 1 | 2011 | 1 | 0.100 |
Why?
|
Horses | 1 | 2011 | 14 | 0.100 |
Why?
|
Specialty Boards | 1 | 2011 | 10 | 0.100 |
Why?
|
Medicine, Traditional | 2 | 2009 | 22 | 0.100 |
Why?
|
Milk | 1 | 2011 | 13 | 0.100 |
Why?
|
Disinfection | 1 | 2011 | 5 | 0.100 |
Why?
|
Drugs, Chinese Herbal | 1 | 2011 | 7 | 0.100 |
Why?
|
Recurrence | 2 | 2003 | 266 | 0.100 |
Why?
|
Wounds, Nonpenetrating | 1 | 2012 | 90 | 0.100 |
Why?
|
Bandages | 1 | 2011 | 34 | 0.100 |
Why?
|
Stress, Psychological | 3 | 2009 | 218 | 0.100 |
Why?
|
Plasticizers | 1 | 2010 | 1 | 0.100 |
Why?
|
Computer Terminals | 1 | 2010 | 1 | 0.100 |
Why?
|
Latex Hypersensitivity | 1 | 2010 | 1 | 0.100 |
Why?
|
Histamine H1 Antagonists | 2 | 2008 | 9 | 0.100 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2010 | 13 | 0.090 |
Why?
|
Immunohistochemistry | 1 | 2012 | 545 | 0.090 |
Why?
|
Nurse Practitioners | 1 | 2010 | 11 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 462 | 0.090 |
Why?
|
Total Quality Management | 1 | 2010 | 18 | 0.090 |
Why?
|
Waiting Lists | 2 | 2007 | 34 | 0.090 |
Why?
|
Carotid Stenosis | 1 | 2011 | 60 | 0.090 |
Why?
|
Pathology, Clinical | 1 | 2010 | 13 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2013 | 195 | 0.090 |
Why?
|
Time | 1 | 2010 | 23 | 0.090 |
Why?
|
Pennsylvania | 2 | 2018 | 84 | 0.090 |
Why?
|
Aging | 1 | 2017 | 953 | 0.090 |
Why?
|
Durable Medical Equipment | 1 | 2010 | 2 | 0.090 |
Why?
|
Ethics, Business | 1 | 2010 | 2 | 0.090 |
Why?
|
Emigration and Immigration | 2 | 2013 | 32 | 0.090 |
Why?
|
Conditioning, Classical | 1 | 2010 | 26 | 0.090 |
Why?
|
Hygiene | 2 | 2007 | 13 | 0.090 |
Why?
|
Hydroxides | 1 | 2009 | 1 | 0.090 |
Why?
|
Mycology | 1 | 2009 | 1 | 0.090 |
Why?
|
Potassium Compounds | 1 | 2009 | 1 | 0.090 |
Why?
|
North Dakota | 1 | 2009 | 3 | 0.090 |
Why?
|
Blood-Borne Pathogens | 1 | 2009 | 7 | 0.090 |
Why?
|
Medical Audit | 1 | 2009 | 16 | 0.090 |
Why?
|
Indicators and Reagents | 1 | 2009 | 14 | 0.090 |
Why?
|
Specimen Handling | 1 | 2009 | 35 | 0.090 |
Why?
|
Sample Size | 2 | 2013 | 39 | 0.090 |
Why?
|
Dermatitis, Phototoxic | 1 | 2009 | 2 | 0.090 |
Why?
|
Boston | 1 | 2009 | 15 | 0.090 |
Why?
|
Observer Variation | 2 | 2020 | 109 | 0.090 |
Why?
|
Deductibles and Coinsurance | 1 | 2009 | 3 | 0.090 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2009 | 60 | 0.080 |
Why?
|
Beauty | 1 | 2008 | 5 | 0.080 |
Why?
|
Rheumatic Diseases | 1 | 2009 | 7 | 0.080 |
Why?
|
Neoplasms, Basal Cell | 1 | 2008 | 2 | 0.080 |
Why?
|
Forecasting | 3 | 2003 | 145 | 0.080 |
Why?
|
Arthralgia | 1 | 2009 | 33 | 0.080 |
Why?
|
Organizational Objectives | 1 | 2008 | 23 | 0.080 |
Why?
|
Signal Transduction | 1 | 2012 | 701 | 0.080 |
Why?
|
Health Maintenance Organizations | 2 | 2006 | 14 | 0.080 |
Why?
|
Adaptation, Physiological | 1 | 2009 | 55 | 0.080 |
Why?
|
Electronics, Medical | 1 | 2008 | 2 | 0.080 |
Why?
|
Microspheres | 1 | 2008 | 44 | 0.080 |
Why?
|
Dermatitis, Irritant | 1 | 2008 | 2 | 0.080 |
Why?
|
Sodium Hypochlorite | 1 | 2008 | 3 | 0.080 |
Why?
|
Diagnostic Tests, Routine | 1 | 2008 | 24 | 0.080 |
Why?
|
Detergents | 1 | 2008 | 17 | 0.080 |
Why?
|
Acute Disease | 2 | 2006 | 255 | 0.080 |
Why?
|
Eye Protective Devices | 1 | 2008 | 6 | 0.080 |
Why?
|
Tuberculin Test | 1 | 2007 | 2 | 0.080 |
Why?
|
Vision Disorders | 1 | 2008 | 24 | 0.080 |
Why?
|
Radiotherapy Dosage | 1 | 2008 | 101 | 0.080 |
Why?
|
Lichen Planus, Oral | 1 | 2008 | 11 | 0.080 |
Why?
|
Toxoplasmosis, Animal | 1 | 2007 | 1 | 0.080 |
Why?
|
Parent-Child Relations | 2 | 2010 | 46 | 0.080 |
Why?
|
Leishmaniasis | 1 | 2007 | 3 | 0.080 |
Why?
|
Receptors, Interleukin-12 | 1 | 2007 | 2 | 0.080 |
Why?
|
Injections, Intravenous | 1 | 2007 | 79 | 0.080 |
Why?
|
Meta-Analysis as Topic | 1 | 2007 | 43 | 0.080 |
Why?
|
Cryptococcosis | 1 | 2007 | 5 | 0.080 |
Why?
|
Artifacts | 1 | 2007 | 40 | 0.080 |
Why?
|
Drug Evaluation | 2 | 2004 | 15 | 0.080 |
Why?
|
Behavior Therapy | 1 | 2008 | 102 | 0.080 |
Why?
|
Prejudice | 1 | 2007 | 50 | 0.080 |
Why?
|
Virus Diseases | 1 | 2007 | 22 | 0.070 |
Why?
|
Ohio | 1 | 2007 | 58 | 0.070 |
Why?
|
Communication Barriers | 1 | 2007 | 22 | 0.070 |
Why?
|
Larva Migrans | 1 | 2007 | 2 | 0.070 |
Why?
|
Drug Therapy | 1 | 2007 | 16 | 0.070 |
Why?
|
Bacterial Infections | 1 | 2007 | 52 | 0.070 |
Why?
|
Medical Staff, Hospital | 1 | 2007 | 19 | 0.070 |
Why?
|
Microcomputers | 1 | 2006 | 6 | 0.070 |
Why?
|
Models, Biological | 1 | 2009 | 397 | 0.070 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2006 | 11 | 0.070 |
Why?
|
Focus Groups | 2 | 2006 | 111 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 877 | 0.070 |
Why?
|
Vitamin A | 1 | 2006 | 21 | 0.070 |
Why?
|
Lipectomy | 2 | 2003 | 9 | 0.070 |
Why?
|
Hydroxyurea | 1 | 2006 | 3 | 0.070 |
Why?
|
Eye Abnormalities | 1 | 2006 | 4 | 0.070 |
Why?
|
Pterygium | 1 | 2006 | 4 | 0.070 |
Why?
|
Radiation Dosage | 2 | 2006 | 81 | 0.070 |
Why?
|
Social Adjustment | 1 | 2006 | 8 | 0.070 |
Why?
|
Health Services Needs and Demand | 1 | 2007 | 82 | 0.070 |
Why?
|
Skin Irritancy Tests | 1 | 2005 | 1 | 0.070 |
Why?
|
Irritants | 1 | 2005 | 2 | 0.070 |
Why?
|
Interferon-gamma | 2 | 2017 | 63 | 0.070 |
Why?
|
Body Size | 1 | 2005 | 32 | 0.070 |
Why?
|
Pleistophora | 1 | 2005 | 1 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2008 | 370 | 0.070 |
Why?
|
Credentialing | 1 | 2005 | 9 | 0.070 |
Why?
|
Dermatomyositis | 1 | 2005 | 19 | 0.070 |
Why?
|
Drug Storage | 1 | 2005 | 4 | 0.070 |
Why?
|
Candidiasis, Cutaneous | 2 | 2002 | 2 | 0.070 |
Why?
|
Nicotine | 1 | 2008 | 171 | 0.070 |
Why?
|
Poultry Products | 1 | 2005 | 14 | 0.060 |
Why?
|
Child Health Services | 1 | 2005 | 24 | 0.060 |
Why?
|
Respiratory Tract Diseases | 1 | 2005 | 34 | 0.060 |
Why?
|
Family Health | 1 | 2005 | 77 | 0.060 |
Why?
|
Educational Measurement | 1 | 2006 | 119 | 0.060 |
Why?
|
Anesthesia | 1 | 2005 | 64 | 0.060 |
Why?
|
Chemexfoliation | 1 | 2004 | 2 | 0.060 |
Why?
|
Therapeutic Equivalency | 1 | 2004 | 2 | 0.060 |
Why?
|
Texas | 1 | 2004 | 36 | 0.060 |
Why?
|
Inpatients | 1 | 2005 | 78 | 0.060 |
Why?
|
Reimbursement Mechanisms | 1 | 2004 | 13 | 0.060 |
Why?
|
Urban Population | 1 | 2005 | 87 | 0.060 |
Why?
|
Morbidity | 1 | 2005 | 98 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2006 | 197 | 0.060 |
Why?
|
Primary Prevention | 1 | 2004 | 54 | 0.060 |
Why?
|
Indians, North American | 1 | 2004 | 109 | 0.060 |
Why?
|
Poultry | 2 | 2014 | 27 | 0.060 |
Why?
|
Keratosis, Seborrheic | 1 | 2003 | 1 | 0.060 |
Why?
|
Handwriting | 1 | 2003 | 2 | 0.060 |
Why?
|
State Government | 1 | 2003 | 32 | 0.060 |
Why?
|
Disaster Planning | 1 | 2003 | 28 | 0.060 |
Why?
|
Rural Population | 1 | 2005 | 274 | 0.060 |
Why?
|
Medicare Part A | 1 | 2003 | 5 | 0.060 |
Why?
|
Medicare Part B | 1 | 2003 | 5 | 0.060 |
Why?
|
Tonsillectomy | 1 | 2003 | 10 | 0.050 |
Why?
|
Acrylic Resins | 1 | 2002 | 2 | 0.050 |
Why?
|
Likelihood Functions | 1 | 2002 | 48 | 0.050 |
Why?
|
Models, Psychological | 1 | 2002 | 24 | 0.050 |
Why?
|
Drug Labeling | 1 | 2002 | 3 | 0.050 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2002 | 16 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2003 | 294 | 0.050 |
Why?
|
Photosensitivity Disorders | 1 | 2002 | 12 | 0.050 |
Why?
|
New York City | 1 | 2002 | 14 | 0.050 |
Why?
|
Maryland | 1 | 2002 | 28 | 0.050 |
Why?
|
Capitation Fee | 1 | 2002 | 3 | 0.050 |
Why?
|
Tinea Versicolor | 1 | 2002 | 1 | 0.050 |
Why?
|
Migraine Disorders | 1 | 2003 | 65 | 0.050 |
Why?
|
California | 1 | 2002 | 64 | 0.050 |
Why?
|
Body Mass Index | 1 | 2005 | 921 | 0.050 |
Why?
|
Disability Evaluation | 1 | 2003 | 236 | 0.050 |
Why?
|
Endpoint Determination | 2 | 2013 | 21 | 0.050 |
Why?
|
Lasers | 1 | 2002 | 21 | 0.050 |
Why?
|
Risk Reduction Behavior | 1 | 2002 | 124 | 0.050 |
Why?
|
Preventive Health Services | 1 | 2002 | 44 | 0.050 |
Why?
|
Asian Americans | 1 | 2002 | 100 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2002 | 320 | 0.050 |
Why?
|
Uncertainty | 1 | 2021 | 13 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2002 | 128 | 0.050 |
Why?
|
Visual Perception | 1 | 2002 | 115 | 0.050 |
Why?
|
Disease Susceptibility | 1 | 2021 | 58 | 0.050 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2021 | 53 | 0.050 |
Why?
|
Hypersensitivity | 2 | 2014 | 27 | 0.050 |
Why?
|
Infectious Disease Medicine | 1 | 2020 | 4 | 0.050 |
Why?
|
Epidemiology | 1 | 2020 | 6 | 0.050 |
Why?
|
Propensity Score | 1 | 2020 | 41 | 0.050 |
Why?
|
Advisory Committees | 1 | 2020 | 37 | 0.050 |
Why?
|
Delphi Technique | 1 | 2020 | 39 | 0.050 |
Why?
|
Genitalia | 1 | 2020 | 8 | 0.050 |
Why?
|
Outpatient Clinics, Hospital | 3 | 2007 | 16 | 0.050 |
Why?
|
Decontamination | 1 | 2020 | 3 | 0.050 |
Why?
|
Equipment Reuse | 1 | 2020 | 5 | 0.050 |
Why?
|
Virus Inactivation | 1 | 2020 | 2 | 0.050 |
Why?
|
Telecommunications | 1 | 2020 | 7 | 0.050 |
Why?
|
Masks | 1 | 2020 | 5 | 0.050 |
Why?
|
Menopause | 1 | 2021 | 92 | 0.050 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2020 | 10 | 0.050 |
Why?
|
Critical Care | 1 | 2020 | 117 | 0.040 |
Why?
|
Commerce | 1 | 2019 | 43 | 0.040 |
Why?
|
Iontophoresis | 1 | 2019 | 6 | 0.040 |
Why?
|
Cholinergic Antagonists | 1 | 2019 | 12 | 0.040 |
Why?
|
Skin Diseases, Bacterial | 1 | 2018 | 3 | 0.040 |
Why?
|
Skin Diseases, Viral | 1 | 2018 | 4 | 0.040 |
Why?
|
Sympathectomy | 1 | 2019 | 22 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2019 | 51 | 0.040 |
Why?
|
Coal Tar | 2 | 2012 | 2 | 0.040 |
Why?
|
Interprofessional Relations | 1 | 2019 | 51 | 0.040 |
Why?
|
New Jersey | 1 | 2018 | 11 | 0.040 |
Why?
|
Half-Life | 1 | 2018 | 22 | 0.040 |
Why?
|
Injections, Intradermal | 1 | 2018 | 7 | 0.040 |
Why?
|
Antipruritics | 1 | 2018 | 6 | 0.040 |
Why?
|
Anesthetics, Combined | 1 | 2018 | 5 | 0.040 |
Why?
|
Anesthesia, Local | 1 | 2018 | 17 | 0.040 |
Why?
|
Janus Kinase 1 | 1 | 2017 | 5 | 0.040 |
Why?
|
Knowledge Bases | 1 | 2017 | 3 | 0.040 |
Why?
|
Receptors, Opioid, kappa | 1 | 2018 | 40 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2017 | 10 | 0.040 |
Why?
|
Adoptive Transfer | 1 | 2017 | 26 | 0.040 |
Why?
|
Genome | 1 | 2017 | 38 | 0.040 |
Why?
|
Vaccination | 1 | 2019 | 137 | 0.040 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2017 | 59 | 0.040 |
Why?
|
Smoking | 2 | 2013 | 493 | 0.040 |
Why?
|
Area Under Curve | 1 | 2016 | 95 | 0.030 |
Why?
|
Agrochemicals | 2 | 2006 | 5 | 0.030 |
Why?
|
Pharmacies | 1 | 2016 | 13 | 0.030 |
Why?
|
ROC Curve | 1 | 2016 | 171 | 0.030 |
Why?
|
Sebum | 1 | 2015 | 1 | 0.030 |
Why?
|
Sebaceous Glands | 1 | 2015 | 2 | 0.030 |
Why?
|
Hair Follicle | 1 | 2015 | 8 | 0.030 |
Why?
|
Nursing | 1 | 2015 | 1 | 0.030 |
Why?
|
Blister | 1 | 2015 | 7 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 736 | 0.030 |
Why?
|
Vidarabine | 1 | 2014 | 6 | 0.030 |
Why?
|
Mutation | 1 | 2017 | 503 | 0.030 |
Why?
|
Transplantation Conditioning | 1 | 2014 | 13 | 0.030 |
Why?
|
Family | 1 | 2015 | 115 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2014 | 37 | 0.030 |
Why?
|
Neck | 1 | 2014 | 26 | 0.030 |
Why?
|
Drug Utilization Review | 2 | 2004 | 17 | 0.030 |
Why?
|
Azathioprine | 1 | 2014 | 24 | 0.030 |
Why?
|
Equipment Safety | 1 | 2014 | 20 | 0.030 |
Why?
|
Head | 1 | 2014 | 49 | 0.030 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 40 | 0.030 |
Why?
|
Thiazolidines | 1 | 2014 | 2 | 0.030 |
Why?
|
Actins | 1 | 2014 | 53 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2014 | 58 | 0.030 |
Why?
|
Epidemiologic Studies | 1 | 2013 | 20 | 0.030 |
Why?
|
Animals, Newborn | 1 | 2014 | 116 | 0.030 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2014 | 69 | 0.030 |
Why?
|
Environment | 1 | 2013 | 52 | 0.030 |
Why?
|
Air Conditioning | 1 | 2013 | 7 | 0.030 |
Why?
|
Humidity | 1 | 2013 | 5 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 117 | 0.030 |
Why?
|
Group Practice | 1 | 2013 | 3 | 0.030 |
Why?
|
Myocytes, Cardiac | 1 | 2014 | 92 | 0.030 |
Why?
|
Private Practice | 1 | 2013 | 4 | 0.030 |
Why?
|
Latin America | 1 | 2013 | 8 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 25 | 0.030 |
Why?
|
Chickens | 1 | 2012 | 38 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2014 | 468 | 0.020 |
Why?
|
Case Management | 1 | 2011 | 5 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 773 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 849 | 0.020 |
Why?
|
Reference Values | 1 | 2010 | 255 | 0.020 |
Why?
|
Motivation | 1 | 2010 | 114 | 0.020 |
Why?
|
Office Management | 1 | 2007 | 2 | 0.020 |
Why?
|
Self Disclosure | 1 | 2008 | 23 | 0.020 |
Why?
|
Time Management | 1 | 2007 | 9 | 0.020 |
Why?
|
Hyperplasia | 1 | 2007 | 38 | 0.020 |
Why?
|
Epidermis | 1 | 2007 | 30 | 0.020 |
Why?
|
Leisure Activities | 1 | 2007 | 13 | 0.020 |
Why?
|
Knowledge | 1 | 2007 | 16 | 0.020 |
Why?
|
Minnesota | 1 | 2006 | 21 | 0.020 |
Why?
|
Rural Health | 1 | 2007 | 44 | 0.020 |
Why?
|
Rhode Island | 1 | 2006 | 5 | 0.020 |
Why?
|
Insect Bites and Stings | 1 | 2006 | 3 | 0.020 |
Why?
|
Plants | 1 | 2006 | 6 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2006 | 100 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2006 | 101 | 0.020 |
Why?
|
Cinnamates | 1 | 2006 | 5 | 0.020 |
Why?
|
Chalcones | 1 | 2006 | 3 | 0.020 |
Why?
|
Propiophenones | 1 | 2006 | 4 | 0.020 |
Why?
|
Water | 1 | 2006 | 57 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2006 | 78 | 0.020 |
Why?
|
Workplace | 1 | 2006 | 47 | 0.020 |
Why?
|
Sunburn | 1 | 2005 | 2 | 0.020 |
Why?
|
Air Pollutants, Occupational | 1 | 2005 | 4 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 2005 | 11 | 0.020 |
Why?
|
Dermabrasion | 1 | 2004 | 2 | 0.020 |
Why?
|
Teratogens | 1 | 2004 | 3 | 0.020 |
Why?
|
Writing | 1 | 2004 | 13 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2004 | 110 | 0.010 |
Why?
|
Comprehension | 1 | 2003 | 21 | 0.010 |
Why?
|
Dihydroxycholecalciferols | 1 | 2003 | 1 | 0.010 |
Why?
|
Anthralin | 1 | 2003 | 2 | 0.010 |
Why?
|
Survival Rate | 1 | 2005 | 894 | 0.010 |
Why?
|
Long-Term Care | 1 | 2003 | 25 | 0.010 |
Why?
|
Diaper Rash | 1 | 2002 | 1 | 0.010 |
Why?
|
Postoperative Period | 1 | 2002 | 100 | 0.010 |
Why?
|
Time and Motion Studies | 1 | 2002 | 5 | 0.010 |
Why?
|